series-a
Stage
1
Investors
About
Cytospire Therapeutics is a UK-based biotech company developing differentiated multispecific immune cell engager antibodies designed to enhance and direct the activity of the body’s own immune system. The company focuses on pan-gamma delta T cell engagers to overcome the limitations of conventional CD3 T cell engagers, particularly in solid tumors.
Explore Cytospire Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.